Opinion|Videos|July 12, 2024 (Updated: July 12, 2024)
ADCs Targeting GI Cancers
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review the data for T-DM1 for:
- HER2+ advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocaricoma: GATSBY; Shah-Gastric Cancer_2019: Biomarker analysis of GATSBY
- T-DM1 + Pertuzumab for HER2-amplified colorectal cancer: HERACLES-B trial
- Please review the data for T-DXd for:
- HER2+ gastric or GEJ: DESTINY-Gastric01; Shitara_Nature Med_2024: Biomarker Analysis of DESTINY-Gastric01 and DESTINY-Gastric02
- Unresectable or metastatic HER2+ CRC: DESTINY-CRC01 1. DESTINY-CRC02 – Raghav_ASCO 2023
- HER2+ and HER2-low GC: DESTINY-Gastric03 Janjigian ASCO 2024
- Retrospective Cohort Study EN-DEAVOR: Nakanishi ASCO 2024
- What is the potential for HER2-targeting ADCs in other GI cancers?
- Biliary Tract Cancers, Pancreatic
- PanTumor02: Meric-Bernstam_J Clin Oncol_2024; a. BTC and PC Cohort Outcomes: Oh ASCO 2024 #4090
- HERB trial (BTC): Ohba_ASCO2022
- Biliary Tract Cancers, Pancreatic
- Where do HER2-directed ADCs fit into the treatment armamentarium for GI cancers?
- Is there an unmet need ADCs could help fill?
Advertisement
Related to this article
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
A triplet combination regimen led to high remission rates in patients with blastic plasmacytoid dendritic cell neoplasm.
The CDH17-targeting antibody-drug conjugate received the designation for previously treated advanced unresectable or metastatic colorectal cancer.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
4
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
5